Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Human Virome01:26

Human Virome

54
The human body harbors a vast and diverse viral community known as the human virome. The virome includes bacteriophages that infect bacteria, and eukaryotic viruses that infect human cells. Transient dietary and environmental viruses also contribute to this dynamic ecosystem. Estimates suggest the human body may contain on the order of 10¹³ viral particles, though abundance varies widely by body site and detection method.Comprehensive characterization of the virome has become possible...
54
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

73
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
73

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monocyte-derived macrophages drive neurological tissue damage through mitochondrial reactive oxygen species.

Science immunology·2026
Same author

Triggering multiple sclerosis: infection with Epstein-Barr virus activates multiple pre-existing autoreactive B and T cells.

Signal transduction and targeted therapy·2026
Same author

LANA-specific CD4<sup>+</sup> effector T cells accumulate at the site of KSHV infection in humanized mice.

Nature communications·2025
Same author

Humanized Mouse Models of Epstein Barr Virus Infection.

Current protocols·2025
Same author

Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies.

Oncoimmunology·2025
Same author

EBV induces CNS homing of B cells attracting inflammatory T cells.

Nature·2025

Related Experiment Video

Updated: May 6, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.1K

Epstein-Barr virus pathogenesis and emerging control strategies.

Christian Münz1

  • 1Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland. christian.muenz@uzh.ch.

Nature Reviews. Microbiology
|April 25, 2025
PubMed
Summary

Epstein-Barr virus (EBV) therapies are advancing for EBV-associated cancers and immune diseases like multiple sclerosis. Novel treatments aim to target the virus directly, offering new hope for various pathologies.

More Related Videos

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

9.1K
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

3.6K

Related Experiment Videos

Last Updated: May 6, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.1K
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

9.1K
Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

3.6K

Area of Science:

  • Virology
  • Immunology
  • Oncology
  • Neurology

Background:

  • Epstein-Barr virus (EBV) was discovered 60 years ago as the first human tumor virus.
  • EBV is implicated in various diseases beyond malignancies, including immunopathologies like multiple sclerosis.
  • Primary EBV infection may trigger autoimmune diseases in susceptible individuals.

Purpose of the Study:

  • To review the broad spectrum of diseases associated with Epstein-Barr virus (EBV).
  • To discuss current and developing therapeutic strategies targeting EBV-associated pathologies.
  • To explore novel approaches for specifically targeting EBV infection programs.

Main Methods:

  • Review of current scientific literature on EBV and associated diseases.
  • Analysis of ongoing clinical trials for EBV-specific therapies and vaccines.
  • Discussion of emerging pharmacological, antibody, cellular, and vaccine-based treatments.

Main Results:

  • EBV is linked to a wide range of diseases, including cancers and autoimmune conditions.
  • Clinical trials for EBV-specific therapies and vaccines are underway.
  • New treatment modalities are showing promise in targeting EBV infection programs.

Conclusions:

  • Advances in EBV-specific therapies offer potential treatments for EBV-associated malignancies and immunopathologies.
  • Novel approaches focus on targeting EBV directly, rather than host cells.
  • Developing treatments may provide new options for managing diverse EBV-related diseases, including multiple sclerosis.